Statin Market Insights and Trends, 2020-2025: Atorvastatin, Fluvastatin, Lovastatin, Pravastatin, Simvastatin, Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Statin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

The global statin market is currently witnessing stable growth.

This report provides a deep insight into the global statin market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc.

The increasing prevalence of hypercholesterolemia across the globe is among the key factors driving the growth of the market. This disorder is highly prevalent among the geriatric population and individuals suffering from other ailments, such as diabetes, obesity and cardiovascular diseases (CVDs), which is facilitating product adoption across both the developed and emerging nations.

Furthermore, increasing consumer preference for over-the-counter (OTC) drugs is another factor contributing to the market growth. In comparison to brand name drugs, OTC variants are usually more affordable. Additionally, the growing adoption of combination therapies that use statin with other cholesterol diminishing compounds, such as ezetimibe, is acting as another growth-inducing factor. Research has found statin-ezetimibe combination therapy to be capable of achieving near-normal lipid profiles in familial hypercholesterolemia patients and significantly reducing the risk of CVDs occurrence.

Other factors, including improving healthcare infrastructure and growing health consciousness among consumers, are projected to drive the market further.

The competitive landscape of the industry has also been examined with some of the key players being Abbott Laboratories, AstraZeneca, Aurobindo Pharma, Biocon, GlaxoSmithKline, Merck & Co., Novartis, Pfizer, etc.

Key Questions Answered

• How has the global statin market performed so far and how will it perform in the coming years?
• What are the key regional markets?
• What is the breakup of the market based on the type?
• What is the breakup of the market based on the therapeutic area?
• What is the breakup of the market based on the drug class?
• What is the breakup of the market based on the application?
• What is the breakup of the market based on the distribution?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the market?
• What is the structure of the global statin market and who are the key players?
• What is the degree of competition in the market?

Key Topics Covered

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

4.1 Overview

4.2 Key Industry Trends

5 Global Statin Market

5.1 Market Overview

5.2 Market Performance

5.3 Market Forecast

6 Market Breakup by Type

6.1 Synthetic Statins

6.2 Natural Statins

7 Market Breakup by Therapeutic Area

7.1 Cardiovascular Disorders

7.2 Obesity

7.3 Inflammatory Disorders

7.4 Others

8 Market Breakup by Drug Class

8.1 Atorvastatin

8.2 Fluvastatin

8.3 Lovastatin

8.4 Pravastatin

8.5 Simvastatin

8.6 Others

9 Market Breakup by Application

9.1 Dyslipidemia

9.2 Others

10 Market Breakup by Distribution

10.1 Hospitals

10.2 Clinics

10.3 Others

11 Market Breakup by Region

11.1 North America

11.2 Europe

11.3 Asia-Pacific

11.4 Latin America

11.5 Middle East & Africa

12 SWOT Analysis

12.1 Overview

12.2 Strengths

12.3 Weaknesses

12.4 Opportunities

12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

14.1 Overview

14.2 Bargaining Power of Buyers

14.3 Bargaining Power of Suppliers

14.4 Degree of Competition

14.5 Threat of New Entrants

14.6 Threat of Substitutes

15 Price Indicators

16 Competitive Landscape

16.1 Market Structure

16.2 Key Players

16.3 Profiles of Key Players

16.3.1 Abbott

16.3.2 AstraZeneca

16.3.3 Aurobindo Pharma

16.3.4 Biocon

16.3.5 GlaxoSmithKline

16.3.6 Merck & Co.

16.3.7 Novartis

16.3.8 Pfizer

For more information about this report visit https://www.researchandmarkets.com/r/26a27s